A clinically conditional deep learning model was reported to classify pituitary neuroendocrine tumor subtypes from routine slides, paired with clinical features. In an internal test set, the model reached 91.8% accuracy across five subtypes, targeting a workflow where pathology interpretation is time-consuming and can vary. For neuroendocrine oncology teams, accurate subtype assignment can affect therapy selection and prognostic stratification, particularly when clinical presentations overlap. The study’s emphasis on “clinically conditional” design suggests the model is built to be used alongside available clinical data rather than in isolation. As with most algorithmic pathology studies, external validation and prospective testing will be critical before clinical integration, but the result strengthens the case for slide-based molecularly-informed risk stratification.